PRESS RELEASE published on 06/26/2024 at 07:30, 4 months 25 days ago Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée. Crossject met en perspective le potentiel de ZEPIZURE® à la lumière des études RAMPART et de bioéquivalence. Analyse des avantages de l'injection IM de midazolam dans la prise en charge des crises d'épilepsie Crossject ZEPIZURE RAMPART Étude De Bioéquivalence Injection IM
BRIEF published on 06/18/2024 at 12:35, 5 months 2 days ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Droits De Vote Capital Social AMF Pharmacie Spécialisée Crossject
BRIEF published on 06/18/2024 at 12:35, 5 months 2 days ago Crossject: Information relating to the total number of voting rights and shares making up the share capital Share Capital Voting Rights AMF Crossject Specialized Pharmacy
PRESS RELEASE published on 06/18/2024 at 12:30, 5 months 2 days ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Publication du nombre total de droits de vote et d'actions de CROSSJECT au 31 mai 2024 conformément aux réglementations. Détails sur le capital social Droits De Vote Capital Social AMF Crossject Pharma
BRIEF published on 06/13/2024 at 09:41, 5 months 8 days ago Crossject : Information sur le nombre de droits de vote et d'actions Droits De Vote Capital Social Actions 2024 Crossject
BRIEF published on 06/13/2024 at 09:41, 5 months 8 days ago Crossject: Information on the number of voting rights and shares Share Capital Voting Rights Actions 2024 Crossject
PRESS RELEASE published on 06/13/2024 at 09:36, 5 months 8 days ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Crossject publie le nombre total de droits de vote et d'actions au 31 mai 2024 conformément aux normes réglementaires Droits De Vote Capital Social Actions Crossject Pharma
BRIEF published on 06/12/2024 at 07:35, 5 months 9 days ago Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer Crossject ZEPIZURE® Dan Chiche Medical Director
BRIEF published on 06/12/2024 at 07:35, 5 months 9 days ago Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Crossject ZEPIZURE® Dan Chiche Directeur Médical
PRESS RELEASE published on 06/12/2024 at 07:30, 5 months 9 days ago Crossject appoints Dan Chiche, MD as Chief Medical Officer North America Crossject appoints Dan Chiche, MD as Chief Medical Officer North America, strengthening leadership team and expanding presence in U.S. Supports ZEPIZURE® regulatory milestones targeting in 2025 North America Chief Medical Officer Crossject ZEPIZURE Dan Chiche
Published on 11/21/2024 at 12:00, 29 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 29 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 59 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 26 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 29 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:15, 14 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 59 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 1 hour 27 minutes ago Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 06:58, 5 hours 31 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 31 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 31 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 21 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 9 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
